Here's Why NuVasive Is Tanking Today
After NuVasive (NASDAQ: NUVA), a medical device maker focused on minimally invasive spine surgery, reported mixed second-quarter earnings results and announced a shake-up in its executive team, its shares had fallen 11% as of 11:45 a.m. EDT.
Here's a quick review of the headline numbers from NuVasive's second quarter:
While the slight miss on revenue could help to explain the sell-off, the markets were caught off guard by the announcement of sweeping changes to the company's executive team:
Source: Fool.com
Johnson & Johnson Aktie
225,10 €
-0,90 %
Starke Kaufsignale für Johnson & Johnson: Keine Sell-Einschätzungen, nur Buy-Einschätzungen.
Mit einem Kursziel von 228 € für Johnson & Johnson ist ein leichter Anstieg gegenüber dem aktuellen Kurs von 225.1 € zu erwarten.
